Thanks a lot, and welcome to Cantargia's Q1 report 2024. It's a pleasure to present the progress we made with the company during the first quarter. So it's been a very good period and a good start of the year for us. During the first quarter, we presented the first clinical results from our CAN10 programme. Uh, and the results were good. So obviously we showed good safety. And we could also show receptor occupancy similar to what we expected from our model. Uh, but on a broader scale here, it actually means that Cantargia now has two clinical projects with recent clinical results, and this is a major step forward for the company. Uh, we also presented new clinical data on our lead program, nadunolimab, during the AACR. Uh, and around a very exciting finding that, not only can it have anti-tumor activity or proposed activity, but it can also reduce neuropathy, which is a very serious side effect of several chemotherapies and also ADCs. And there is going to be a presentation around this at ASCO in two weeks from now. So we very much look forward to updating you on that. Uh, at a later time point. Uh, also with nadunolimab, we got regulatory approval to start the phase 2b trial in pancreatic cancer. And after the period, we also had lots of new data being presented in various journals. And it was all related to systemic sclerosis today, which was published in a very high-impact journal. Data was presented on systemic sclerosis in a very high-impact journal. And finally, we also got a paper on the structure, function relationships and CAN10's mechanism of action, being published in another high-quality journal. And finally, just a few days ago, uh. And we'll come back to this later on. Uh, we had, let's say, clearance of one of our remaining patent appeals or oppositions. So there has been an appeal around one of our not a core patents, but an obviously important patent. But the third party withdrew that appeal, and that is obviously very good, because now we can continue to focus on nadunolimab and moving the product forward. So if we look into the status of a project and look at our pipeline. So not only is nadunolimab being developed quite broadly in cancer, the most mature data has been generated in pancreatic cancer, triple-negative breast cancer, and non-small cell lung cancer. And we'll come back to where we are in those programs. But the CAN10 program is also making progress, now still in clinical phase 1 but advancing quickly towards phase 2, starting next year. And the lead indications here are myocarditis and systemic sclerosis. And finally, we have our platform program CAN10 which consists of a number of antibodies that can be moved forward in the future. So in 2024 and 2025, there is a lot of things happening. So we have data coming up from two clinical programs, both CAN10 and additionally nadunolimab. And there are several other clinical milestones from the ongoing programs or new trials to start during 2024 and 2025. And there are publications and conferences coming up. So we made presentations at AACR. We're going to do a major presentation at ASCO. And I'm sure it's going to be much more and already rich with content. We have had three publications in impactful journals and presentations at conferences. And again, I expect much, much more during the rest of 2020 and next year. So now I would like to focus a little bit more on the content program to start with. It is a program where lots of things are happening both within the program but also in the environment around, which really increases the attention on this program. And the main reason is that CAN10 is a unique molecule because it's not only targeting specific cytokines; it's really targeting a whole family, the IL-1 family. And there is lots of evidence that the IL-1 family, which includes IL-1, IL-33, and IL-36, are driving inflammatory diseases by working together as a family. So there are lots of diseases. And we'll come back to that, showing that we can kind of regulate and operate together. And even more excitingly, there are lots of data showing that, for instance, IL-1 beta blockade, IL-6 blockade gives some signal of activity or even works in diseases where these systems are highly upregulated. But in most cases, it's not really translated into strong clinical efficacy. And there's more and more data being accumulated that it's because it's only a blocking of one of these compounds being done, which leads to a signal but not activity. But if you block them together, you will get some kind of additive or synergistic effect. And I think that's really triggering the interest around this compound. So basically what CAN10 is doing if you look at this slide is that it's binding to IL1RAP, which is a coreceptor IL-1 alpha IL-33 and IL-36. And it's blocking all of them by binding at one receptor. It blocks the binding of IL-1 receptor, IL-33 receptor, and IL-36 receptor, thereby shutting down the activity of this molecule. This molecule is completely. And if you look down here on this slide, this is really trying to illustrate what we're trying to achieve. If we have a biological system where IL-33 and IL-36 are all active and try to block one of the molecules, So if you're trying to block IL-1 with anakinra, IL-33 with the IL-33 receptor, or IL-36 with an IL-36 blocker, They are not very effective. But if you look at the blue line, you have a very potent inhibition which can turn. And this is really illustrating what we're trying to do in these diseases. And with the first in human studies ongoing, we're conducting a. A single ascending dose part, which means that you're applying single doses and it's going very well. We have not seen any safety signals and we have documented receptor occupancy. During Q3, we expect to start with subcutaneous administration in the pouch. So that's multiple dosing. And here we will now switch to psoriasis patients where there is a strong rationale for blocking all of these cytokines. So if you look at the right you can see in psoriasis which is represented by a gray bar here, you have an upregulation of IL-1 alpha, IL-1 beta, IL-36, so obviously blocking all of them at the same time could have a very interesting effect. And that's what we're trying to document. But clearly, psoriasis is an indication which is not of choice for the initial phase two. Where there are very active agents out there. And it would be a major commitment to start over. But in the future, who knows? But we've done animal models as well to prove that we can have efficacy in psoriasis models, which is only picked up with Cantargia's nardunolimab and not with anti-IL-1 beta, for instance. And in this multi-pot, we will do lots of biomarker analysis in addition to what's already been done in the set. And very quickly going through some of the preclinical data that was presented during the period. And this is in systemic sclerosis, where we take fibroblasts from patients. And what we can show here is that if we block the activity of these fibroblasts, which is part of the disease in systemic sclerosis, we can do that very efficiently with Cantargia's CAN10, even if we stimulate with TGF-beta or with IL-1 beta, IL-33 and IL-36. So this is clearly a very strong signal that we're on the right track. And we have previously presented animal models showing that, for instance, in this bleomycin model, that we have an active compound when it comes to skin fibrosis, which is on par with intravenous endothelin-1 blockers, which are used to some extent in systemic sclerosis. But to some extent those are limited by toxicity. So then moving over to nadunolimab, and here the news that was presented during the period was the neuropathy signal and neuropathy. It is a very serious medical condition which is unfortunately induced by several chemotherapies. And one central component in this chemotherapy-induced neuropathy relates to neuroinflammation, which is driven by the IL-1 system. And we have previously presented that we had a very low incidence of grade three neuropathies in these patients. In our pancreatic cancer trial where we studied Gemcitabine and Abraxane in combination with nadunolimab, so we had only a 1% incidence. Versus expected more than 10% from historical controls. But the signals that have now been taken forward. We can also see a significant signal if you look at the low-grade neuropathy. And that's something that will be presented at ASCO. And we have also done animal models. And we will present that work as well at ASCO. So I hope this will be something very exciting which will be disclosed in the near future. And then just to put this in perspective. So the new data will show that we can get rid of, or at least minimize, some very serious side effects of chemotherapy. But we've already previously shown that when we add nadunolimab to chemotherapy, there is a signal of activity both on survival and PFS. So the survival of 13.2 months, it's much, much better than you expect from, historical controls, which is more in the 9 to 10 months range. And to further strengthen those data, we also saw that patients with the highest IL1RAP have the strongest activity signal. So here the survival is more than 14 months. And this is very logical given that we have an antibody therapy targeting IL1RAP. More IL1RAP, very small tumors, and more antibodies can get in, bind and have activity in triple-negative breast cancer. Here we have a randomized phase 2b trial ongoing. It's going to be about two groups of 50 patients in the trial. We started with a lead-in phase which has been presented before. And again, we have good response rates, promising PFS, and survival. And we are very much looking forward to presenting randomized data later this year. So really, to summarize, nadunolimab shows lots of activity and it will be further explored. We have one randomized trial ongoing and two clinical trials starting this year. We have a pancreatic cancer phase 2b trial. And we also have an investigator-sponsored trial in leukemia, which is also funded by a very prestigious grant from the US Department of Defense. And there is more to come. So, before going into the financials, I would just highlight that Cantargia has a very strong IP position. We have composition of matter patents on both nadunolimab, which is expiring in 2045. We have a composition of matter patent expiring in 2041. We also have patents around the targets. And those patents have been the subject of several oppositions and appeals. But all of these, applications have ended up in a very favorable way for Cantargia. And the final appeal we had, in front of us, was relating to the solid tumor patent. But here, the third party who filed the appeal decided to withdraw, which means that all these patents are now valid and remain in force. So, this is obviously a very good step forward for Cantargia. So by that, I would like to hand over to Jörg Distler, who can present a little bit about the finances.